**About the Special Issue Editors**

**Frédéric Hollande** obtained his PhD in 1994 from the University of Montpellier, France. He worked as a Research Fellow for CNRS (France) from 1996 to 2012, studying molecular mechanisms that underlie the progression of colon cancer. In parallel with his academic work, he co-founded in 2007 a small biotech company developing therapeutic monoclonal antibodies. He was the joint-scientific director of this company and designed its Intellectual Property portfolio until 2011. Fred also headed the Oncology Research Department at the Institute of Functional Genomics of Montpellier in 2011– 2012. Fred moved to Melbourne in September 2012 to take up a position at the Department of Pathology at the University of Melbourne. He currently is the Deputy Head of Department @ Dept of Clinical Pathology. He leads a research group and a tumour organoid platform at the University of Melbourne Centre for Cancer Research, located within the Victorian Comprehensive Cancer Centre. His research interests include the analysis of cancer stem cell regulation by their surrounding environment, as well as the study of the impact of inter and intra-tumour heterogeneity on metastatic progression and treatment response. His work focuses on cancers with poor clinical outcomes, such as advanced/metastatic colorectal cancer and, more recently, pancreatic cancer.

**Delphine Merino** is a faculty member and laboratory head at the Olivia Newton-John Cancer Research Institute, in Melbourne, Australia. Her current research interests are focussed on understanding the cellular and molecular events regulating breast cancer progression and drug resistance. Her team uses patient samples and patient-derived xenografts to dissect the journey of human metastases and to study tumour heterogeneity. A major focus of Dr Merino's research is on identifying the survival pathways responsible for the spread of cancer cells to different metastatic sites. Understanding how cancer cells survive in their microenvironment and resist current treatments will ultimately lead to the identification of new therapies for the treatment of advanced breast cancer.
